ALBANY, N.Y., Sept. 4, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI)
announced today that it has expanded into the protein market, with
an initial focus on protein expression and purification. The global
revenue of the total proteomics market is anticipated to grow at a
compound annual growth rate of about 4.1% to about $9.2 billion by 20181.
AMRI's current and ongoing activities – as part of its
New York State Public-Private
Partnership in Buffalo, N.Y. –
encompass the production of purified recombinant proteins as
reagents and tools for biological assays and sterile, pyrogen-free
materials for proof-of-concept, non-human in vivo studies.
Current production capabilities range from a scale of 1 to 100
milligrams. The protein expression systems and methods of focus are
E. coli, mammalian and baculovirus.
"As a company with a deep history of discovery innovation, we
continue to explore scientific solutions that provide our customers
with enhanced flexibility and access to state-of-the-art science
and technologies," said Michael A.
Luther, Ph.D., MBA, Senior Vice President of Discovery and
Development at AMRI. "We are very excited to be able to offer these
expanded biology services as we continue to work with our
customers, partners, CNSE, and the State
of New York, to provide relevant drug discovery services,
cutting-edge platforms and expertise to academia and the global
Bio-Pharmaceutical industry from early discovery to candidate
selection and beyond."
"Under Governor Andrew Cuomo's
Buffalo Billion Initiative, we look forward to working with AMRI
to provide these vital new services at the
Buffalo Medical Innovation and Commercialization (BMIC) Hub to
support pharmaceutical development, technology optimization, and
related research and development opportunities," said Michael Liehr, Executive Vice President of
Innovation and Technology and Vice President for Research of the
SUNY CNSE/SUNYIT institution, a lead partner in the BMIC Hub. "The
expansion to protein R&D will further leverage scientific
knowledge and expertise to produce industry-changing results for
stakeholders at every level."
As part of its aim to provide customers with high-value services
in the area of biology and pharmacology, AMRI unveiled an
IND-enabling support services platform in March 2014. This platform of services is aimed at
supporting the successful initiation and completion of customer IND
programs. As part of this offering, AMRI now provides in
vitro DMPK studies related to drug-drug interactions and
metabolism, which are routinely included in IND submissions.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Bio-Pharmaceutical industry to improve
patient outcomes and the quality of life for more than two decades.
With locations in North America,
Europe and Asia, our key business segments include Large
Scale Manufacturing (LSM) and Discovery and Development Solutions
(DDS). The LSM segment includes Active Pharmaceutical Ingredients
(API) and Drug Product Manufacturing, which supports the commercial
cGMP manufacturing of complex APIs, starting materials, clinical
formulation development and aseptic fill and finish. Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug
metabolism and pharmacokinetics, as well as natural products. For
more information about AMRI, please visit our website at
www.amriglobal.com or follow us on Twitter (@amriglobal).
About AMRI Discovery and Development Solutions
(DDS)
Bolstered by over 20 years of strong scientific
expertise and contributions to drug discovery and development,
Discovery & Development Solutions (DDS) provides a suite of
comprehensive scientific solutions from design to execution for
early drug discovery to IND Investigational New Drug (IND) and
beyond. We offer biological and pharmacological capabilities from
assay design, development and implementation to reiterative lead
optimization, as well as DMPK, formulation, and regulatory support.
In addition to library and compound design, synthesis, and process
design with rapid scale-up, AMRI provides diverse chemistry
experience including, but not limited to, flow,
biocatalysis and commercial-focused process chemistries,
as well as capabilities in separation, analytical, bioanalytical
and formulation sciences. AMRI also has expertise and capabilities
from collections to manufacturing for natural products and
semi-synthetics. For natural products, we can screen, profile,
isolate and elucidate novel and unique products as well as scale
the production for these natural products using our bio-processing
capabilities.
AMRI and the BMIC Hub
The Buffalo Medical Innovation
and Commercialization Hub (the "BMIC Hub") at Buffalo Niagara
Medical Campus is a new public-private pharmaceutical research and
development initiative in Buffalo,
N.Y. announced by New York
Governor Andrew M. Cuomo in
December 2012. The BMIC Hub is a
collaboration that involves AMRI and other industry partners to
provide life science discovery services, cutting-edge platforms and
expertise to academia and industry from early discovery to
candidate selection and beyond.
1. Source BCC Research "Life Science Tools and Reagents: Global
Markets" January 2014.
SOURCE AMRI